Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock Short Interest Report for October

Posted by Teresa Graham on Nov 4th, 2026

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 108,814 shares, a decline of 33.9% from the September 30th total of 164,505 shares. Currently, 2.3% of the company’s shares are sold short. Based on an average daily trading volume, of 39,300 shares, the short-interest ratio is currently 2.8 days.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Check Out Our Latest Report on Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Price Performance

SNOA opened at $1.14 on Wednesday. The firm has a market capitalization of $5.46 million, a PE ratio of -0.93 and a beta of 1.31. The business’s 50-day moving average is $1.23 and its two-hundred day moving average is $1.70. Sonoma Pharmaceuticals has a 1 year low of $0.85 and a 1 year high of $3.95.

Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%. The firm had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million.

Sonoma Pharmaceuticals Company Profile

(Get Free Report)

Sonoma Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment.

The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions.